Colesevelam for the Treatment of Bile Acid Malabsorption in Patients With Crohn's Disease
- Conditions
- Crohns DiseaseBile Acid Malabsorption
- Interventions
- Drug: Placebo
- Registration Number
- NCT01203254
- Lead Sponsor
- Florian Beigel
- Brief Summary
The purpose of this study is to assess the efficacy of cholestagel to reduce the frequency of soft and liquid stools per day in patients with CD in clinical remission with symptoms of BAM and to assess the improvement in stool consistency and quality of life in these patients and to assess the safety of cholestagel.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- TERMINATED
- Sex
- All
- Target Recruitment
- 34
Not provided
Not provided
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Arm && Interventions
Group Intervention Description Placebo Placebo - Cholestagel Colesevelam -
- Primary Outcome Measures
Name Time Method Reduction of fluid stool > 30 % 4 weeks after baseline
- Secondary Outcome Measures
Name Time Method Improvement of Stool Consistency 4 weeks after baseline Proportion of patients on cholestagel compared to placebo that reaches improvement of stool consistency on the Bristol stool chart of at least one point.
Improvement of Quality of Life. 4 weeks after baseline Proportion of patients on cholestagel compared to placebo that reaches an improvement of the Quality of Life.
Change of median liquid or soft stool frequency/per day. 4 weeks after baseline
Trial Locations
- Locations (6)
Praxis Dr. Mroß
🇩🇪Berlin, Germany
Hochschulambulanz Med. Klinik I - Charite-
🇩🇪Berlin, Germany
Hamburgisches Forschungsinstitut für CED
🇩🇪Hamburg, Germany
Universitätsklinikum des Saarlandes -Innere Medizin-
🇩🇪Homburg, Germany
Internistische Gemeinschaftspraxis
🇩🇪Leipzig, Germany
CED - Zentrum der Universität München - Klinikum Grosshadern
🇩🇪Munich, Germany